Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Target Price
The average target price of ATRC is 52 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell